Introduction and Overview of Oral Controlled Release Formulation Design

Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice

Volumn , Issue , 2010, Pages 1-19

  Wen, Hong ^a   Park, Kinam ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b PURDUE UNIVERSITY   (United States)

Author keywords

Nonconventional oral controlled delivery systems; Optimal formulation and process selection for controlled release drugs; Oral controlled release formulation design

Indexed keywords

EID: 80052841393     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470640487.ch1     Document Type: Chapter

References (157)

1. Abdul S, Poddar SS. A flexible technology for modified release of drugs: multilayered tablets. J. Control. Release 2004;97(3):393-405.
2. Bartholomaeus J, Ziegler I. Delayed-release formulation of 3- (3-dimethylamino-1-ethyl-2-methyl-propyl)phenol. WO Patent 2003035054, 2003.
3. Lerner EI, Flashner-Barak M, Achthovem EV, Keegstra H, Smit R. Delayed release formulations of 6-mercaptopurine. WO Patent 2005099666, 2005.
4. Prakash A, Markham A. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease. Drugs 1999;57(3):383-408.
5. Sharma SK, Ruggenenti P, Remuzzi G. Managing hypertension in diabetic patients-focus on trandolapril/verapamil combination. Vasc. Health Risk Manage. 2007;3(4):453-465.
6. Simon S. Opioids and treatment of chronic pain: understanding pain patterns and the role for rapid-onset opioids. Med. Gen. Med. 2005;7(4):54.
7. Alaux G, Lewis G, Andre F. Controlled-release dosage forms comprising a short acting hypnotic or a salt. EP Patent 1005863, 2000.
8. Hainer JW, Sugg J. Metoprolol succinate extended release/ hydrochlorothiazide combination tablets. Vasc. Health Risk Manage. 2007;3(3):279-288.
9. Ahlskog JE. Treatment of early Parkinson's disease: are complicated strategies justified? Mayo Clin. Proc. 1996;71(7): 659-670.
10. Divoll M, Greenblatt DJ, Ochs HR, Shader RI. Absolute bioavailability of oral and intramuscular diazepam: effects of age and sex. Anesth. Analg. 1983;62(1):1-8.
11. Salzman C, Shader RI, Greenblatt DJ, Harmatz JS. Long v short half-life benzodiazepines in the elderly. Kinetics and clinical effects of diazepam and oxazepam. Arch. Gen. Psychiatry 1983;40(3):293-297.
12. Swartz CM, Sherman A. The treatment of tricyclic antidepressant overdose with repeated charcoal. J. Clin. Psychopharmacol. 1984;4(6):336-340.
13. Hoffman A, Horwitz E, Hess S, Cohen-Poradosu R, Kleinberg L, Edelberg A, Shapiro M. Implications on emergence of antimicrobial resistance as a critical aspect in the design of oral sustained release delivery systems of antimicrobials. Pharm. Res. 2008;25(3):667-671.
14. Awan NA, Amsterdam EA, Vera Z, DeMaria AN, Miller RR, Mason DT. Reduction of ischemic injury by sublingual nitroglycerin in patients with acute myocardial infarction. Circulation 1976;54(5):761-765.
15. Anon. Oxymorphone-Endo/Penwest: EN 3202, EN 3203. Drugs R&D 2003;4(3):204-206.
16. Anon. Metformin extended release-DepoMed: metformin, metformin gastric retention, metformin GR. Drugs R&D 2004;5(4):231-233.
17. Arthur RMF, Mehmel H. A sustained release formulation of isosorbide-5-mononitrate with a rapid onset of action. Int. J. Clin. Pract. 1999;53(3):205-212.
18. Klein E. The role of extended-release benzodiazepines in the treatment of anxiety: a risk-benefit evaluation with a focus on extended-release alprazolam. J. Clin. Psychiatry 2002;63 (Suppl. 14):27-33.
19. Hutton JT, Morris JL. Long-acting carbidopa-levodopa in the management of moderate and advanced Parkinson's disease. Neurology 1992;42 (1 Suppl. 1):51-56; discussion 57-60.
20. Anonymous. Controlled-release budesonide in Crohn's disease. Drug Ther. Bull. 1997;35(4):30-31.
21. McCarberg B. Tramadol extended-release in the management of chronic pain. Ther. Clin. Risk Manage. 2007;3(3):401-410.
22. Michel MC. A benefit-risk assessment of extended-release oxybutynin. Drug Saf. 2002;25(12):867-876.
23. Pieper John A. Understanding niacin formulations. Am. J. Manage. Care 2002;8 (12 Suppl.):S308-S314.
24. Wagstaff AJ, Goa KL. Once-weekly fluoxetine. Drugs 2001;61(15):2221-2228.
25. Michelson EL. Calcium antagonists in cardiology: update on sustained-release drug delivery systems. Clin. Cardiol. 1991;14(12):947-950.
26. Khor S-P, Hsu A. The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease. Curr. Clin. Pharmacol. 2007;2(3):234-243.
27. Hoffman A, Stepensky D, Lavy E, Eyal S, Klausner E, Friedman M. Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms. Int. J. Pharm. 2004;277 (1-2):141-153.
28. Tuerck D, Wang Y, Maboudian M, Sedek G, Pommier F, Appel-Dingemanse S. Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations inman. Int. J. Clin. Pharmacol. Ther. 2007;45(12):662-668.
29. Shirwaikar AA, Srinatha A. Sustained release bi-layered tablets of diltiazem hydrochloride using insoluble matrix system. Indian J. Pharm. Sci. 2004;66(4):433-437.
30. ShahAC, Britten NJ, Olanoff LS, Badalamenti JN. Gel-matrix systems exhibiting bimodal controlled release for oral drug delivery. J. Control. Release 1989;9(2):169-175.
31. Maroni A, Zema L, Cerea M, Sangalli ME. Oral pulsatile drug delivery systems. Expert Opin. Drug Deliv. 2005;2 (5):855-871.
32. Ghimire M, McInnes FJ, Watson DG, Mullen AB, Stevens HNE. In-vitro/in-vivo correlation of pulsatile drug release from press-coated tablet formulations: a pharmacoscintigraphic study in the beagle dog. Eur. J. Pharm. Biopharm. 2007;67(2):515-523.
33. Mohamad A, Dashevsky A. In vitro and in vivo performance of a multiparticulate pulsatile drug delivery system. Drug Dev. Ind. Pharm. 2007;33(2):113-119.
34. Zou H, Jiang X,Kong L, Gao S. Design and evaluation of a dry coated drug delivery system with floating-pulsatile release. J. Pharm. Sci. 2008;97(1):263-273.
35. McCall TW, Baichwal AR, Staniforth JN. TIMERx oral controlled-release drug delivery system. Drugs Pharm. Sci. 2003;126:11-19.
36. Staniforth JN, Baichwal AR. TIMERx: novel polysaccharide composites for controlled/programmed release of drugs in the gastrointestinal tract. Expert Opin. Drug Deliv. 2005;2 (3):587-595.
37. Ritschel WA. Targeting in the gastrointestinal tract: new approaches. Methods Find. Exp. Clin. Pharmacol. 1991;13 (5):313-336.
38. Yu LX, Amidon GL. Characterization of small intestinal transit time distribution in humans. Int. J. Pharm. 1998;171 (2):157-163.
39. Yu LX, Crison JR, Amidon GL. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int. J. Pharm. 1996;140(1):111-118.
40. Youngberg CA, Berardi RR, Howatt WF, Hyneck ML, Amidon GL, Meyer JH, Dressman JB. Comparison of gastrointestinal pH in cystic fibrosis and healthy subjects. Dig. Dis. Sci. 1987;32(5):472-480.
41. Gruber P, Longer MA, Robinson JR. Some biological issues in oral, controlled drug delivery. Adv. Drug Deliv. Rev. 1987;1 (1):1-18.
42. Wagener S, Shankar KR,Turnock RR, Lamont GL, BaillieCT. Colonic transit time-what is normal? J. Pediatr. Surg. 2004;39(2):166-169; discussion 166-169.
43. Bouchoucha M, Devroede G, Faye A, Arsac M. Importance of colonic transit evaluation in the management of fecal incontinence. Int. J. Colorectal Dis. 2002;17(6):412-417; discussion 418-419.
44. Arhan P, Devroede G, Jehannin B, Lanza M, Faverdin C, Dornic C, Persoz B, Tetreault L, Perey B, Pellerin D. Segmental colonic transit time. Dis. Colon Rectum 1981;24 (8):625-629.
45. Grundy JS, Foster RT. The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. Clin. Pharmacokinet. 1996;30(1):28-51.
46. John VA, Shotton PA, Moppert J, Theobald W. Gastrointestinal transit of Oros drug delivery systems in healthy volunteers: a short report. Br. J. Clin. Pharmacol. 1985;19 (Suppl. 2):203S-206S.
47. Alvisi V, Gasparetto A, Dentale A, Heras H, Felletti-Spadazzi A, D'Ambrosi A. Bioavailability of a controlled release formulation of ursodeoxycholic acid in man. Drugs Exp. Clin. Res. 1996;22(1):29-33.
48. Heinig R, Ahr G, Hayauchi Y, Kuhlmann J. Pharmacokinetics of the controlled-release nisoldipine coat-core tablet formulation. Int. J. Clin. Pharmacol. Ther. 1997;35(8):341-351.
49. Davis SS. Formulation strategies for absorption windows. Drug Discov. Today 2005;10(4):249-257.
50. Lindenbaum J, Rund DG, Butler VP Jr, Tse-Eng D, Saha JR. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N. Engl. J. Med. 1981;305(14):789-794.
51. Saha JR, Butler VP Jr, Neu HC, Lindenbaum J. Digoxininactivating bacteria: identification in human gut flora. Science 1983;220(4594):325-327.
52. Warrington SJ, Barclay SP, JohnVA, Shotton PA,Wardle HM, Good W. Influence of site of drug delivery on the systemic availability of metoprolol: comparison of intragastric infusion and 14/190 Oros administration. Br. J. Clin. Pharmacol. 1985;19 (Suppl. 2):219S-224S.
53. Paul W, Sharma Chandra P. Tricalcium phosphate delayed release formulation for oral delivery of insulin: a proof-ofconcept study. J. Pharm. Sci. 2008;97(2):863-870.
54. Senel S, Kremer M, Nagy K, Squier C. Delivery of bioactive peptides and proteins across oral (buccal) mucosa. Curr. Pharm. Biotechnol. 2001;2(2):175-186.
55. Soares AF, Carvalho RdA, Veiga F. Oral administration of peptides and proteins: nanoparticles and cyclodextrins as biocompatible delivery systems. Nanomedicine 2007;2 (2):183-202.
56. Amidon GL, Lennernaes H, Shah VP, Crison JR.A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995;12(3):413-420.
57. Shokri J, Ahmadi P, Rashidi P, Shahsavari M, Rajabi-Siahboomi A, Nokhodchi A. Swellable elementary osmotic pump (SEOP): an effective device for delivery of poorly watersoluble drugs. Eur. J. Pharm. Biopharm. 2008;68 (2):289-297.
58. Jacob JS, Bassett M, Schestopol MA, Mathiowitz E, Nangia A, Carter B, Moslemy P, Shaked Ze, Enscore D, Sikes C., Polymeric drug delivery system for hydrophobic drugs. WO Patent 2005084639, 2005.
59. Yu LX. An integrated model for determining causes of poor oral drug absorption. Pharm. Res. 1999;16 (12):1883-1887.
60. Backensfeld T. Pharmaceutical preparation with delayed release of an active substance. WO Patent 2000076484, 2000.
61. Liu L, Khang G, Rhee JM, Lee HB. Monolithic osmotic tablet system for nifedipine delivery. J. Control. Release 2000;67 (2-3):309-322.
62. Barzegar-Jalali M, Adibkia K, Mohammadi G, Zeraati M, Bolagh Behnaz Aghaee G, Nokhodchi A. Propranolol hydrochloride osmotic capsule with controlled onset of release. Drug Deliv. 2007;14(7):461-468.
63. Makhija Sapna N, Vavia Pradeep R. Controlled porosity osmotic pump-based controlled release systems of pseudoephedrine. I. Cellulose acetate as a semipermeable membrane. J. Control. Release 2003;89(1):5-18.
64. Wakode R, Bhanushali R, Bajaj A. Development and evaluation of push-pull based osmotic delivery system for pramipexole. PDA J. Pharm. Sci. Technol. 2008;62(1):22-31.
65. Prabakaran D, Singh P, Kanaujia P, Jaganathan KS, Rawat A, Vyas SP. Modified push-pull osmotic system for simultaneous delivery of theophylline and salbutamol: development and in vitro characterization. Int. J. Pharm. 2004;284 (1-2):95-108.
66. Cardinal J. Formulation of controlled/modified release dosage forms. In AAPS 41st Annual Pharmaceutical Technologies Arden Conference: Oral Controlled Release Development and Technology, 2006.
67. Rudnic EM, Burnside BA, Flanner HH, Wassink SE, Couch RA, Pinkett JE.Soluble form osmotic dose delivery system for glipizide and other drugs. US Patent 6,361,796, 2002.
68. Rudnic EM, Burnside BA, Flanner HH, Wassink SE, Couch RA.Soluble osmotic drug delivery system. WO Patent 9818452, 1998.
69. Chen C-M, Chou JCH. Polymers for once daily pharmaceutical tablet having a unitary core. US Patent 6,485,748, 2002.
70. Sriwongjanya M, Weng T, Chou J, Chen C-M. Controlled release oral dosage form. WO Patent 9961005, 1999.
71. Thombre AG, Appel LE, Chidlaw MB, Daugherity PD, Dumont F, Evans LAF, Sutton SC. Osmotic drug delivery using swellable-core technology. J. Control. Release 2004;94 (1):75-89.
72. Thombre AG, Cardinal JR, Fournier LA. A delivery device containing a poorly water-soluble drug in a hydrophobic medium: ruminal delivery application. J. Control. Release 1992;18(3):221-233.
73. Johnson BA,Waterman KC.Asymmetric membrane polymeric coating for osmotic dosage form for varenicline, for treatment of nicotine dependency. US Patent 2007248671, 2007.
74. Haslam JL, Rork GS.Controlled porosity osmotic pump for controlled-release of diltiazem L-malate. EP Patent 309051, 1989.
75. Bajpai SK, Bajpai M, Saxena S. Ion exchange resins in drug delivery. Ion Exchange Solvent Extr. 2007;18:103-150.
76. Raghunathan Y. Controlled release pharmaceutical preparations. EP Patent 171528, 1986.
77. Raghunathan Y, Amsel L, Hinsvark O, Bryant W. Sustainedrelease drug delivery system I: coated ion-exchange resin system for phenylpropanolamine and other drugs. J. Pharm. Sci. 1981;70(4):379-384.
78. Heil MF, Wilson G. Multi-phase release methscopolamine compositions. US Patent 2008064694, 2008.
79. Jeong SH, Park K. Development of sustained release fast-disintegrating tablets using various polymer-coated ion-exchange resin complexes. Int. J. Pharm. 2008;353(1-2):195-204.
80. Jadhav KR, Chandra M, Kurm SD, Kadam VJ. Ion exchange resins: a novel way to solve formulation problems. Curr. Drug Ther. 2007;2(3):205-209.
81. Thombre AG. Assessment of the feasibility of oral controlled release in an exploratory development setting. Drug Discov. Today 2005;10(17):1159-1166.
82. Vazquez MJ, Perez-Marcos B, Gomez-Amoza JL, Martinez- Pacheco R, Souto C, Concheiro A. Influence of technological variables on release of drugs from hydrophilic matrixes. Drug Dev. Ind. Pharm. 1992;18(11-12):1355-1375.
83. Cao Q-R, Kim T-W, Lee B-J. Photoimages and the release characteristics of lipophilic matrix tablets containing highly water-soluble potassium citrate with high drug loadings. Int. J. Pharm. 2007;339(1-2):19-24.
84. Huet de Barochez B, Lapeyre F, Cuine A. Oral sustained release dosage forms-comparison between matrixes and reservoir devices. Drug Dev. Ind. Pharm. 1989;15 (6-7):1001-1020.
85. KearyCM,Sheskey PJ. Preliminary report of the discovery of a new pharmaceutical granulation process using foamed aqueous binders. Drug Dev. Ind. Pharm. 2004;30(8):831-845.
86. Sheskey PJ, Keary CM. Process for coating solid particles. WO Patent 2003020247, 2003.
87. Iyer RM, Sandhu HK, Shah NH, Phuapradit W, Ahmed HM. Scale-up of extrusion and spheronization. Drugs Pharm. Sci. 2006;157:325-369.
88. Simonoska Crcarevska M, Glavas Dodov M, Goracinova K. Chitosan coated Ca-alginate microparticles loaded with budesonide for delivery to the inflamed colonic mucosa. Eur. J. Pharm. Biopharm. 2008;68(3):565-578.
89. Murata Y, Jinno D, Liu D, Isobe T, Kofuji K, Kawashima S. The drug release profile from calcium-induced alginate gel beads coated with an alginate hydrolysate. Molecules 2007;12 (11):2559-2566.
90. Huang J,Wong HL, Zhou Y,Wu XY, Grad H, Komorowski R, Friedman S. In vitro studies and modeling of a controlledrelease device for root canal therapy. J. Control. Release 67 (2-3): 2000; 293-307.
91. Zhou Y, Wu XY. Theoretical analyses of dispersed-drug release from planar matrices with a boundary layer in a finite medium. J. Control. Release 2002;84(1-2):1-13.
92. Sune NM, Gani R, Bell G, Shirley I. Computer-aided and predictive models for design of controlled release of pesticides. Comput. Aided Chem. Eng. 2004;14:301-306.
93. Wu SXY. Computer-aided design for modified release dosage forms (CAD-MRDF). In AAPS 41st Annual Pharmaceutical Technologies Arden Conference: Oral Controlled Release Development and Technology, 2006.
94. Patel M, Patel B, Patel R, Patel J, Bharadia P, Patel M. Carbopol: a versatile polymer. Drug Deliv. Technol. 2006;6 (3):32-34, 36, 38, 40-43.
95. Alderman DA. A review of cellulose ethers in hydrophilic matrixes for oral controlled-release dosage forms. Int. J. Pharm. Technol. Product Manuf. 1984;5(3):1-9.
96. Salsa T, Veiga F, Pina ME. Oral controlled-release dosage forms. I. Cellulose ether polymers in hydrophilic matrixes. Drug Dev. Ind. Pharm. 1997;23(9):929-938.
97. Vueba ML, Batista de Carvalho LAE, Veiga F, Sousa JJ, Pina ME. Role of cellulose ether polymers on ibuprofen release from matrix tablets. Drug Dev. Ind. Pharm. 2005;31 (7):653-665.
98. Paavola A, Yliruusi J, Kajimoto Y, Kalso E, Wahlstroem T, Rosenberg P. Controlled release of lidocaine from injectable gels and efficacy in rat sciatic nerve block. Pharm. Res. 1995;12(12):1997-2002.
99. Obaidat AA, Rashdan LA, Najib NM. Release of dextromethorphan hydrobromide from matrix tablets containing sodium carboxymethyl cellulose and hydroxypropyl methyl cellulose. Acta Pharm. Turc. 2002;44(2):97-104.
100. Michailova V, Titeva S, Kotsilkova R. Rheological characteristics and diffusion processes in mixed cellulose hydrogel matrices. J. Drug Deliv. Sci. Technol. 2005;15(6):443-449.
101. Tonnesen Hanne H, Karlsen J. Alginate in drug delivery systems. Drug Dev. Ind. Pharm. 2002;28(6):621-630.
102. Miller DA, Fukuda M, McGinity JW. The properties of chitosan as a retardant binder in matrix tablets for sustained drug release. Drug Deliv. Technol. 2006;6(9):44, 46, 48-50, 52.
103. Bialer M. Pharmacokinetic evaluation of sustained release formulations of antiepileptic drugs. Clinical implications. Clin. Pharmacokinet. 1992;22(1):11-21.
104. Blondeau JM. Current issues in the management of urinary tract infections: extended-release ciprofloxacin as a novel treatment option. Drugs 2004;64(6):611-628.
105. Piscitelli DA, Young D. Setting dissolution specifications for modified-release dosage forms. Adv. Exp. Med. Biol. 1997;423:159-166.
106. Kamba M, Seta Y, Takeda N, Hamaura T, Kusai A, Nakane H, Nishimura K. Measurement of agitation force in dissolution test and mechanical destructive force in disintegration test. Int. J. Pharm. 2003;250(1):99-109.
107. Kamba M, Seta Y, Kusai A, Nishimura K. Comparison of the mechanical destructive force in the small intestine of dog and human. Int. J. Pharm. 2002;237(1-2):139-149.
108. Kamba M, Seta Y, Kusai A, Nishimura K. Evaluation of the mechanical destructive force in the stomach of dog. Int. J. Pharm. 2001;228(1-2):209-217.
109. Hayashi T, Kanbe H, Okada M, Suzuki M, Ikeda Y, Onuki Y, Kaneko T, Sonobe T. Formulation study and drug release mechanism of a new theophylline sustained-release preparation. Int. J. Pharm. 304(1-2): 2005; 91-101.
110. Burke MD, Maheshwari CR, Zimmerman BO. Pharmaceutical analysis apparatus and method. WO Patent 2006052742, 2006.
111. Dowell JA, Hussain A, Devane J, Young D. Artificial neural networks applied to the in vitro-in vivo correlation of an extended-release formulation: initial trials and experience. J. Pharm. Sci. 1999;88(1):154-160.
112. Young D. In vitro-in vivo correlation for modified release parenteral drug delivery systems. Drugs Pharm. Sci. 2007;165:141-151.
113. Piscitelli DA, Bigora S, Propst C, Goskonda S, Schwartz P, Lesko LJ, Augsburger L, Young D. The impact of formulation and process changes on in vitro dissolution and the bioequivalence of piroxicam capsules. Pharm. Dev. Technol. 1998; 3(4):443-452.
114. Mandal U, Ray KK, Gowda V, Ghosh A, Pal TK. In-vitro and in-vivo correlation for two gliclazide extended-release tablets. J. Pharm. Pharmacol. 2007;59(7):971-976.
115. Dutta S, QiuY, Samara E, Cao G, Granneman GR. Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a level A in vitro-in vivo correlation (IVIVC). J. Pharm. Sci. 2005;94(9):1949-1956.
116. Meron GD. The development of the swallowable video capsule (M2A). Gastrointest. Endosc. 2000;52(6):817-819.
117. Podczeck F, Course N, Newton JM, Short MB. Gastrointestinal transit of model mini-tablet controlled release oral dosage forms in fasted human volunteers. J. Pharm. Pharmacol. 2007;59(7):941-945.
118. Melia CD, Rajabi-Siahboomi AR, Bowtell RW. Magnetic resonance imaging of controlled release pharmaceutical dosage forms. Pharm. Sci. Technol. Today 1998;1(1): 32-39.
119. Talukder R, Fassihi R. Gastroretentive delivery systems: a mini review. Drug Dev. Ind. Pharm. 2004;30(10):1019-1028.
120. Hwang S-J, Park H, Park K. Gastric retentive drug delivery systems. Crit. Rev. Ther. Drug Carrier Syst. 1998;15 (3):243-284.
121. Nakagawa T, Kondo S-I, Sasai Y, Kuzuya M. Preparation of floating drug delivery system by plasma technique. Chem. Pharm. Bull. 2006;54(4):514-518.
122. Sriamornsak P, Thirawong N, Puttipipatkhachorn S. Emulsion gel beads of calcium pectinate capable of floating on the gastric fluid: effect of some additives, hardening agent or coating on release behavior of metronidazole. Eur. J. Pharm. Sci. 2005;24(4):363-373.
123. Clarke GM, Newton JM, Short MB. Comparative gastrointestinal transit of pellet systems of varying density. Int. J. Pharm. 1995;114(1):1-11.
124. Devereux JE, Newton JM, Short MB. The influence of density on the gastrointestinal transit of pellets. J. Pharm. Pharmacol. 1990;42(7):500-501.
125. Weon KY, Kim DW, Kim JS, Kim K.Gastric retention-type pellet and preparation. WO Patent 2008010690, 2008.
126. Jackson SJ, Bush D, Perkins AC. Comparative scintigraphic assessment of the intragastric distribution and residence of cholestyramine, Carbopol 934P and sucralfate. Int. J. Pharm. 2001;212(1):55-62.
127. Park H, Robinson JR. Mechanisms of mucoadhesion of poly(acrylic acid) hydrogels. Pharm. Res. 1987;4 (6):457-464.
128. Klausner EA, Lavy E, Stepensky D, Friedman M, Hoffman A. Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on riboflavin absorption in dogs. Pharm. Res. 2002;19(10):1516-1523.
129. Cargill R, Engle K, Gardner CR, Porter P, Sparer RV, Fix JA. Controlled gastric emptying. II. In vitro erosion and gastric residence times of an erodible device in beagle dogs. Pharm. Res. 1989;6(6):506-509.
130. Cargill R, Caldwell LJ, Engle K, Fix JA, Porter PA, Gardner CR. Controlled gastric emptying. I. Effects of physical properties on gastric residence times of nondisintegrating geometric shapes in beagle dogs. Pharm. Res. 1988;5 (8):533-536.
131. Lapidot N, Afargan M, Kirmayer D, Kluev L, Cohen M, Moor E, Navon N.A gastro-retentive multi-layered system for the oral delivery of macromolecules. WO Patent 2007093999, 2007.
132. Omidian H, Park K, Rocca JG. Recent developments in superporous hydrogels. J. Pharm. Pharmacol. 2007;59 (3):317-327.
133. Yang S, Park K, Rocca JG. Semi-interpenetrating polymer network superporous hydrogels based on poly(3-sulfopropyl acrylate, potassium salt) and poly(vinyl alcohol): synthesis and characterization. J. Bioactive Compat. Polym. 2004;19 (2):81-100.
134. Qiu Y, Park K. Superporous IPN hydrogels having enhanced mechanical properties. AAPS PharmSciTech 2003;4 (4):406-412.
135. Gemeinhart RA, Park H, Park K. Effect of compression on fast swelling of poly(acrylamide-co-acrylic acid) superporous hydrogels. J. Biomed. Mater. Res. 2000;55(1):54-62.
136. Asghar LFA, Chandran S. Multiparticulate formulation approach to colon specific drug delivery: current perspectives. J. Pharm. Pharm. Sci. 2006;9(3):327-338.
137. Cardinal J. Non-conventional oral controlled drug delivery systems including bioadhesive and site specific systems. In AAPS 41st Annual Pharmaceutical Technologies Arden Conference: Oral Controlled Release Development and Technology, 2006.
138. Kaur G, Jain S, Tiwary AK. Recent approaches for colon drug delivery. Recent Pat. Drug Deliv. Formul. 2007;1(3):222-229.
139. Patel M, Shah T, Amin A. Therapeutic opportunities in colonspecific drug-delivery systems. Crit. Rev. Ther. Drug Carrier Syst. 2007;24(2):147-202.
140. Singh BN. Modified-release solid formulations for colonic delivery. Recent Pat. Drug Deliv. Formul. 2007;1(1):53-63.
141. Mukherji G,Wilson CG. Enteric coating for colonic delivery. Drugs Pharm. Sci. 2003;126:223-232.
142. Kelm GR, Kondo K, Nakajima A. Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery. US Patent 5,914,132, 1999.
143. Watanabe S, Kawai H, Katsuma M, Fukui M.Colon-specific drug release system. WO Patent 9528963, 1995.
144. Korstanje C. The improved cardiovascular safety of omnic (tamsulosin) oral controlled absorption system (OCAS). Eur. Urol. Suppl. 2005;4(7):10-13.
145. Yang L,Watanabe S, Li J, Chu JS, Katsuma M, Yokohama S, Fix JA. Effect of colonic lactulose availability on the timing of drug release onset in vivo from a unique colon-specific drug delivery system (CODES). Pharm. Res. 2003;20(3):429-434.
146. Katsuma M, Watanabe S, Kawai H, Takemura S, Masuda Y, Fukui M. Studies on lactulose formulations for colon-specific drug delivery. Int. J. Pharm. 2002;249(1-2):33-43.
147. Birudaraj R, Mahalingam R, Li X, Jasti BR. Advances in buccal drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 2005;22(3):295-330.
148. Yukimatsu K, Nozaki Y, Kakumoto M, Ohta M. Development of a trans-mucosal controlled-release device for systemic delivery of antianginal drugs pharmacokinetics and pharmacodynamics. Drug Dev. Ind. Pharm. 1994;20 (4):503-534.
149. Gandhi RB, Robinson JR. Oral cavity as a site for bioadhesive drug delivery. Adv. Drug Deliv. Rev. 1994;13 (1-2):43-74.
150. Patel M, Patel B, Patel R, Patel J, Bharadia P, Patel M. Carbopol: a versatile polymer. Drug Deliv. Technol. 2006;6 (3):32-34, 36, 38, 40-43.
151. Park H, Robinson JR. Mechanisms of mucoadhesion of poly (acrylic acid) hydrogels. Pharm. Res. 1987;4(6):457-464.
152. Park K, Robinson JR. Bioadhesive polymers as platforms for oral-controlled drug delivery: method to study bioadhesion. Int. J. Pharm. 1984;19(2):107-127.
153. Park CR, Munday DL. Evaluation of selected polysaccharide excipients in buccoadhesive tablets for sustained release of nicotine. Drug Dev. Ind. Pharm. 2004;30(6): 609-617.
154. Sandri G, Bonferoni MC, Ferrari F, Rossi S, Caramella C. Differentiating factors between oral fast-dissolving technologies. Am. J. Drug Deliv. 2006;4(4):249-262.
155. SastrySV, Nyshadham J. Process development and scale-up of oral fast-dissolving tablets. Drugs Pharm. Sci. 2005;145:311-336.
156. Parakh SR, Gothoskar AV. A review of mouth dissolving tablet technologies. Pharm. Technol. 2003;27(11):92, 94, 96, 98, 100.
157. Davidson C. Oral controlled release development and technology-patent protection for controlled release products. In AAPS 41st Annual Pharmaceutical Technologies Arden Conference: Oral Controlled Release Development and Technology, 2006.